Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod F Bonnet, Bousquet J
Service de Pneumologie et Réanimation, Hôpital de l'Hôtel-Dieu, Paris, 1 Place du Parvis Notre Dame, 75181, Cedex 04, France.
Respir Med. 2009 Jan;103(1):41-9. doi: 10.1016/j.rmed.2008.09.002. Epub 2008 Nov 1.
Lung deposition is crucial for asthma treatment. However, there is no study comparing the potential role of lung co-deposition of combination therapy (inhaled corticosteroid and long-acting beta2 agonist) in the same inhaler. In moderate to severe asthmatics, an extra-fine hydrofluoroalkane combination of beclomethasone dipropionate and formoterol given via a single pressurised metered-dose inhaler (pMDI) was compared with beclomethasone dipropionate chlorofluorocarbon (CFC) pMDI and formoterol dry powder inhaler (DPI) given via separate inhalers.
In a double-blind, double-dummy, 24-week randomised clinical trial, 645 patients with moderate to severe asthma uncontrolled by regular treatment with inhaled corticosteroids received regular treatment with extra-fine fixed combination beclomethasone dipropionate 200 microg/formoterol 12 microg bid, or beclomethasone dipropionate (500 microg bid) via CFC pMDI and formoterol (12 microg bid) via DPI, or beclomethasone dipropionate (500 microg bid) via CFC pMDI. The primary outcome was morning peak expiratory flow (PEF). Secondary outcomes included lung function measured at clinic, asthma symptoms and control, exacerbations.
Beclomethasone dipropionate/formoterol combination via single inhaler or via separate inhalers improved morning PEF. However, the combination via single inhaler was more effective than given via separate inhalers for asthma control. Both combination treatments were superior to beclomethasone dipropionate alone in improving lung function and asthma control. All treatments were well tolerated.
In patients with moderate to severe asthma, beclomethasone dipropionate/formoterol in a single inhaler was as effective as beclomethasone dipropionate plus formoterol and superior to beclomethasone dipropionate alone in improving lung function. For the first time with a single inhaler, beclomethasone dipropionate/formoterol was significantly superior to separate components for asthma control.
肺部沉积对哮喘治疗至关重要。然而,尚无研究比较联合疗法(吸入性糖皮质激素和长效β2受体激动剂)在同一吸入器中肺部共同沉积的潜在作用。在中度至重度哮喘患者中,将通过单一压力定量吸入器(pMDI)给予的丙酸倍氯米松和福莫特罗的超细微氢氟烷烃联合制剂与通过单独吸入器给予的丙酸倍氯米松氯氟烃(CFC)pMDI和福莫特罗干粉吸入器(DPI)进行了比较。
在一项双盲、双模拟、为期24周的随机临床试验中,645例接受吸入性糖皮质激素常规治疗但未得到控制的中度至重度哮喘患者接受以下常规治疗:通过单一吸入器给予超细微固定复方制剂丙酸倍氯米松200微克/福莫特罗12微克,每日两次;或通过CFC pMDI给予丙酸倍氯米松(每日两次,500微克)并通过DPI给予福莫特罗(每日两次,12微克);或通过CFC pMDI给予丙酸倍氯米松(每日两次,500微克)。主要结局指标为早晨呼气峰流速(PEF)。次要结局指标包括在诊所测量的肺功能、哮喘症状及控制情况、病情加重情况。
通过单一吸入器或通过单独吸入器给予的丙酸倍氯米松/福莫特罗联合制剂均改善了早晨PEF。然而,对于哮喘控制,通过单一吸入器给予的联合制剂比通过单独吸入器给予的更有效。两种联合治疗在改善肺功能和哮喘控制方面均优于单独使用丙酸倍氯米松。所有治疗的耐受性均良好。
在中度至重度哮喘患者中,单一吸入器中的丙酸倍氯米松/福莫特罗在改善肺功能方面与丙酸倍氯米松加福莫特罗效果相当,且优于单独使用丙酸倍氯米松。丙酸倍氯米松/福莫特罗首次通过单一吸入器在哮喘控制方面显著优于单独的成分。